Company news

MaaT Pharma news in 2026

MaaT Pharma's news releases, calls and decks from 2026, newest first.

View company

MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors

October 19, 2026

MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update

September 29, 2026

MaaT Pharma publie ses résultats semestriels 2026 et fait le point sur ses activités

September 28, 2026

MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors

September 21, 2026

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

September 18, 2026

MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe

September 15, 2026

MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

July 6, 2026

MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

June 29, 2026

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

May 26, 2026

MaaT Pharma Announces Provides an Update on the Application for Marketing Authorization of MaaT013 in the treatment of acute Graft-versus-Host Disease

May 21, 2026

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

May 20, 2026

MaaT Pharma to Hold Annual General Meeting on June 16, 2026

May 11, 2026

MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal

April 1, 2026

MaaT Pharma Announces 2025 Annual Results and Provides Business Updates

March 31, 2026

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

March 23, 2026

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

March 9, 2026

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

February 3, 2026

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

January 20, 2026

Decks in 2026